Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Enzon and Hisun Announce Strategic Alliance for PEGylation Technology in China

publication date: May 8, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Enzon and Zhejiang Hisun today announced a strategic alliance for the development of therapeutics using Enzon's Customized PEGylation Linker Technology. The agreement also included Hisun licensing China rights for Enzon’s novel anti-cancer drug, PEG-SN38. Enzon will receive an upfront fee, milestone payments and high single-digit royalties on net sales while retaining ex-China rights. Detailed financial terms of the agreement were not disclosed. More details…

Stock symbol: (NASDAQ: ENZN; SSE: 600267)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...